共 77 条
[1]
Jermal A(2009)Cancer statistics, 2009 CA Cancer J Clin 59 225-249
[2]
Siegel R(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[3]
Ward E(2009)Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 5513-5518
[4]
Burris HA(2006)Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 3946-3952
[5]
Moore MJ(2007)Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2212-2217
[6]
Anderson J(2009)Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30 minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 3778-3785
[7]
Cunningham D(2006)A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Br J Cancer 95 587-592
[8]
Chau I(2005)Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509-3516
[9]
Stocken DD(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960-1966
[10]
Heinemann V(2010)Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial J Clin Oncol 28 15s-175